论文部分内容阅读
目的:探讨康柏西普联合雷珠单抗治疗年龄相关性黄斑变性(AMD)的临床疗效。方法:选择2015年6月到2016年10月我院收治的60例AMD患者,按随机数字表法分为对照组和治疗组。对照组患者给予康柏西普治疗,治疗组患者给予康柏西普联合雷珠单抗治疗,两组患者均治疗3个月。评价并比较两组患者临床疗效。统计并比较两组患者治疗后的视网膜渗漏总改善率。观察并比较两组患者治疗前后最佳矫正视力和黄斑视网膜厚度。结果:治疗后,治疗组患者的视力提高率为80.00%,明显高于对照组的55.00%,差异具有统计学意义(X~2=4.104,P=0.043)。治疗后,治疗组患者的视网膜渗漏总改善率为92.50%,明显高于对照组的70.00%,差异具有统计学意义(X~2=5.294,P=0.021)。治疗前,两组患者最佳矫正视力、黄斑视网膜厚度比较差异无统计学意义(P>0.05);治疗后,两组患者最佳矫正视力均明显大于治疗前,黄斑视网膜厚度均明显小于治疗前,并且治疗组均明显优于对照组,差异均具有统计学意义(P<0.05)。结论:康柏西普联合雷珠单抗治疗AMD的临床疗效显著,能够明显提高视力,减轻视网膜渗漏,值得在临床上推广应用。
Objective: To investigate the clinical efficacy of concomitant ranibizumab in the treatment of age-related macular degeneration (AMD). Methods: Sixty AMD patients admitted to our hospital from June 2015 to October 2016 were randomly divided into control group and treatment group. Patients in the control group were treated with Compstatin, and patients in the treatment group were treated with Compstax combined with ranibizumab. Both groups were treated for 3 months. The clinical efficacy was evaluated and compared between the two groups. Statistics and comparison of two groups of patients after treatment, the total rate of improvement of retinal leakage. The best corrected visual acuity and macular retinal thickness before and after treatment were observed and compared between two groups. Results: After treatment, the improvement of visual acuity in the treatment group was 80.00%, which was significantly higher than that in the control group (55.00%). The difference was statistically significant (X ~ 2 = 4.104, P = 0.043). After treatment, the total improvement rate of retinal leakage in the treatment group was 92.50%, which was significantly higher than that in the control group (70.00%). The difference was statistically significant (X ~ 2 = 5.294, P = 0.021). Before treatment, the two groups of patients with the best corrected visual acuity, macular retinal thickness was no significant difference (P> 0.05); after treatment, the best corrected visual acuity was significantly greater in both groups before treatment, macular retinal thickness were significantly less than before treatment , And the treatment group were significantly better than the control group, the difference was statistically significant (P <0.05). Conclusions: Compaqib combined with ranibizumab in the treatment of AMD clinical significant effect, can significantly improve visual acuity, reduce retinal leakage, it is worth in the clinical application.